



[Go to Product page](#)

Datasheet for ABIN7200671

Recombinant anti-CTLA-4 (Ipilimumab Biosimilar) antibody

Overview

Quantity:	1 mg
Target:	CTLA-4 (Ipilimumab Biosimilar)
Reactivity:	Human
Host:	Mouse
Antibody Type:	Recombinant Antibody
Clonality:	Monoclonal
Conjugate:	This CTLA-4 (Ipilimumab Biosimilar) antibody is un-conjugated
Application:	Flow Cytometry (FACS), In vivo Studies (in vivo)

Product Details

Purpose:	Ipilimumab Biosimilar, Human CTLA-4 Monoclonal Antibody
Immunogen:	The anti-human CTLA-4 monoclonal antibody ipilimumab biosimilar was produced in the ipilimumab biosimilar CHO stable cell line.
Isotype:	IgG1 kappa
Specificity:	The in vivo grade ipilimumab biosimilar specifically binds to the human CTLA4.
Characteristics:	Recombinant fully human IgG1 monoclonal antibody.
Purification:	Protein A affinity column
Purity:	> 95% by SDS-PAGE under reducing conditions and HPLC.
Sterility:	0.2 µm filtered
Endotoxin Level:	< 1 EU per 1 mg of the protein by the LAL method.

Target Details

Target:	CTLA-4 (Ipilimumab Biosimilar)
Abstract:	CTLA-4 (Ipilimumab Biosimilar) Products
Target Type:	Biosimilar
Background:	<p>What is Ipilimumab biosimilar research grade? Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.</p> <p>Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.</p> <p>Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.</p>

Application Details

Application Notes:	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ipilimumab.
Restrictions:	For Research Use only

Handling

Format:	Liquid
Concentration:	1 mg/mL
Buffer:	PBS, pH 7.4, no stabilizers or preservatives.
Preservative:	Without preservative
Handling Advice:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Storage:	-20 °C
Storage Comment:	12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Expiry Date:	12 months